ARTICLE | Finance
Plus fundings for Asher, Pathios, Outrun and Theolytics
By Paul Bonanos, Director of Biopharma Intelligence, and Gunjan Ohri, Data Content Analyst
April 18, 2024 9:38 PM UTC


Backed by VCs at Arch and a team from The Medicines Co., obesity and metabolic disease start-up Metsera is developing a pipeline the company believes will be differentiated due to its therapies’ duration of effect, next-generation targets and combination approaches.
Arch Venture Partners and Population Health Partners (PHP) have launched Metsera Inc. with $290 million in initial funding, with the aim of developing best-in-class injectable and oral therapies for weight loss, obesity-related disorders and metabolic diseases. The latter firm was formed by former executives at The Medicines Co. in the wake of its 2019 acquisition by Novartis AG (SIX:NOVN; NYSE:NVS) for $9.7 billion…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652156/venture-report-metsera-s-290m-launch-regeneron-s-new-vc-fund